APO-RIVASTIGMINE rivastigmine (as hydrogen tartrate) 6mg capsule blister pack

País: Austràlia

Idioma: anglès

Font: Department of Health (Therapeutic Goods Administration)

ingredients actius:

rivastigmine hydrogen tartrate, Quantity: 9.6 mg

Disponible des:

Arrotex Pharmaceuticals Pty Ltd

Designació comuna internacional (DCI):

rivastigmine hydrogen tartrate

formulario farmacéutico:

Capsule

Composición:

Excipient Ingredients: maize starch; microcrystalline cellulose; Gelatin; iron oxide red; stearic acid; titanium dioxide; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Vía de administración:

Oral

Unidades en paquete:

112, 28, 56, 14

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the Alzheimer's type

Resumen del producto:

Visual Identification: Hard gelatine calsule with orange, opaque body and red opaque cap. Imprinted "APO R6" in black ink, white to off white fill.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius

Estat d'Autorització:

Registered

Data d'autorització:

2010-07-27